Fate Therapeutics Inc. Common Stock (FATE)

FairStock Score: 55/100 — STEADY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I approach Fate Therapeutics as a Graham-style analyst, and the first fact is that it earns no profit. At the $2.00 close on 2026-10-13, the market cap was $239.6M; FairStock shows P/E -1.90 and P/B 1.53. The business is a clinical-stage biotech developing programmed cell therapies. In fiscal Q2 2026, the quarter ended 2026-06-30, revenue was $2.1M and net loss was $30.2M. For FY2025, the year ended 2025-12-31, revenue was $6.6M and net loss was $136.3M; for FY2024, the year ended 2024-12-31, revenue was $13.6M and net loss was $186.3M; for FY2023, the year ended 2023-12-31, revenue was $63.5M and net loss was $160.9M. Revenue has shrunk sharply, and the company remains deeply unprofitable. The loss narrowed from FY2024 to FY2025, but the absolute numbers still require outside funding. Trailing free cash flow was -$105.7M, with a FairStock FCF yield of -44.1%, while FairStock calculates Piotroski 2/9 and Altman Z-Score -7.05. Debt/equity is 0.49 and beta is 2.55. I see no financial moat; any competitive advantage would have to come from pipeline data, which the figures do not yet show. FairStock's Lynch category is none because it lost money in each of the last four years. The FairStock Score is 55/100. Valuation rests on future clinical success, not present earnings. Without profits, book value and cash are the only valuation anchors, and the cash burn is heavy. I would call it speculative, not a Graham bargain.

In plain English: Fate Therapeutics is a medical research company trying to develop cell-based treatments for cancer and immune disorders. The business looks weak today: it is not profitable, sales are tiny and shrinking, and it spends a lot of cash. At $2.00 per share, the price does not look clearly cheap or expensive based on current numbers; it is mostly a bet on future research results.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer